Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Breast Cancer

Free Subscription 24.11.2025 1 AJR Am J Roentgenol 1 Am J Clin Pathol 1 Am J Epidemiol 5 Ann Oncol 5 Ann Surg Oncol 3 BMC Cancer 1 Br J Cancer 3 Breast Cancer 3 Breast Cancer (Dove Med Press) 2 Breast Cancer Res 10 Breast Cancer Res Treat 1 Breast J 4 Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 1 Cell 6 Clin Breast Cancer 1 Clin Cancer Res 3 Eur J Cancer 1 Eur J Surg Oncol 2 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Natl Cancer Inst 2 J Surg Oncol 1 Lancet 1 Mod Pathol 1 Mol Ther Oncol 3 NPJ Breast Cancer 2 Oncogene 1 Oncol Rep 1 PLoS Comput Biol 4 PLoS One 2 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 3 Radiol Imaging Cancer 1 Radiology 3 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. KERLIKOWSKE K, Sprague BL, Miglioretti DL
   Stable False-Negative Rates for Mammography in the Breast Cancer Surveillance Consortium Over Time.
   AJR Am J Roentgenol. 2025 Nov 19. doi: 10.2214/AJR.25.34200.
   PubMed        
   
   

   
   Am J Clin Pathol

2. KORIE U, Ai D, Podany P, Zhang H, et al
   Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study.
   Am J Clin Pathol. 2025;164:704-711.
   PubMed         Abstract available
   
   

   
   Am J Epidemiol

3. BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al
   The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation.
   Am J Epidemiol. 2025;194:3316-3324.
   PubMed         Abstract available
   
   

   
   Ann Oncol

4. GUTTERY DS, Shaw JA, Stebbing J
   Intercepting endocrine resistance in ER+/HER2- metastatic breast cancer: Insights from the PADA-1 trial.
   Ann Oncol. 2025 Nov 15:S0923-7534(25)06261-1. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   
5. TOSS A, Blondeaux E, Tenedini E, Bonamici L, et al
   ASSOCIATION BETWEEN TYPE AND LOCATION OF GERMLINE BRCA1/2 PATHOGENIC OR LIKELY PATHOGENIC VARIANTS WITH PHENOTYPE AND PROGNOSIS IN YOUNG PATIENTS WITH BREAST CANCER: RESULTS FROM AN INTERNATIONAL COHORT STUDY.
   Ann Oncol. 2025 Nov 17:S0923-7534(25)06262-3. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
6. SAURA C, Cortes J, Modi S, Kim SB, et al
   Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03.
   Ann Oncol. 2025 Nov 17:S0923-7534(25)06265-9. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
7. CABEL L, Berger F, Bachelot T, Pistilli B, et al
   Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.
   Ann Oncol. 2025 Nov 17:S0923-7534(25)06260-X. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
8. HURVITZ SA, Loi S, O'Shaughnessy J, Okines AFC, et al
   Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.
   Ann Oncol. 2025 Nov 17:S0923-7534(25)06263-5. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

9. KOBZEVA-HERZOG AJ, Palaniappan S, Jiangliu Y, Kraus E, et al
   ASO Visual Abstract: A Multidisciplinary Breast Cancer Clinic Improves Time to Treatment at an Urban, Safety Net Hospital.
   Ann Surg Oncol. 2025 Nov 15. doi: 10.1245/s10434-025-18677.
   PubMed        
   
   
10. MARTELLI G
    ASO Author Reflections: No Further Axillary Treatment is Safe if the Sentinel Nodes are Negative After Neoadjuvant Chemotherapy in cT2 cN1 Breast Cancer.
    Ann Surg Oncol. 2025 Nov 15. doi: 10.1245/s10434-025-18775.
    PubMed        
    
    
11. VAN GEMERT D, Beelen LM, Mos J, van Egdom L, et al
    Breast Cancer-Related Lymphedema (BCRL): Comprehensive Characterization of Patients Seeking Microsurgical Treatment.
    Ann Surg Oncol. 2025 Nov 18. doi: 10.1245/s10434-025-18694.
    PubMed         Abstract available
    
    
12. MARTELLI G, Barretta F, Muzi C, Listorti C, et al
    Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study.
    Ann Surg Oncol. 2025 Nov 18. doi: 10.1245/s10434-025-18673.
    PubMed         Abstract available
    
    
13. YOO JW, Byeon J, Park WK, Kim J, et al
    Germline BRCA1/2 Mutation Prevalence in Unselected ER-Low/HER2-Negative Breast Cancer.
    Ann Surg Oncol. 2025 Nov 14. doi: 10.1245/s10434-025-18713.
    PubMed         Abstract available
    
    

    
    BMC Cancer

14. FANG Q, Sanderson RW, Zilkens R, Boman I, et al
    Diagnostic feasibility study of stereoscopic optical palpation for breast tumour margin assessment.
    BMC Cancer. 2025;25:1793.
    PubMed         Abstract available
    
    
15. LOZA P, Irmejs A, Daneberga Z, Maksimenko J, et al
    The difference in contralateral breast cancer and ovarian cancer risks for BRCA1 founder variant (c.5266dup, c.4035del) carriers with primary breast cancer.
    BMC Cancer. 2025;25:1769.
    PubMed         Abstract available
    
    
16. CHEN Q, Xiong J, Wang H, Xu Y, et al
    A nomogram for breast cancer brain metastasis patients after stereotactic radiotherapy.
    BMC Cancer. 2025;25:1784.
    PubMed         Abstract available
    
    

    
    Br J Cancer

17. VEIGA LHS, Gierach GL, Smith SA, Howell RM, et al
    Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors.
    Br J Cancer. 2025 Nov 14. doi: 10.1038/s41416-025-03240.
    PubMed         Abstract available
    
    

    
    Breast Cancer

18. SASADA S, Tsuji W, Watanabe N, Shimo A, et al
    Breast reconstruction-related complications from postmastectomy radiation therapy in stage II-III breast cancer: sub-analysis of a multi-institutional observational study (Reborn-03).
    Breast Cancer. 2025 Nov 18. doi: 10.1007/s12282-025-01799.
    PubMed         Abstract available
    
    
19. ALTUNDAG K
    Improving response evaluation and treatment adaptation in hormone receptor-positive/human epidermal growth factor receptor 2-positive breast cancer.
    Breast Cancer. 2025 Nov 18. doi: 10.1007/s12282-025-01801.
    PubMed        
    
    
20. DA ROCHA AS, Fernandes GA, de Toledo Osorio CAB, de Freitas Junior R, et al
    Overall survival of patients with second primary breast cancer associated with molecular subtype and epidemiological profile at a cancer center.
    Breast Cancer. 2025 Nov 19. doi: 10.1007/s12282-025-01766.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

21. HELAL ASF, Ali SM, Hassan MHI, Elrefaey BH, et al
    Circuit Weight Training Enhances Quality of Life and Functional Outcomes in Breast Cancer Survivors: A Randomized Controlled Trial.
    Breast Cancer (Dove Med Press). 2025;17:1025-1039.
    PubMed         Abstract available
    
    
22. WANG H, Huang C, Wang Y, Liu Y, et al
    Preoperative Imaging Assessment of Lymphovascular Invasion in Breast Cancer: Current Evidence, Technical Advances, and Future Directions.
    Breast Cancer (Dove Med Press). 2025;17:1051-1062.
    PubMed         Abstract available
    
    
23. CAO H, Gao F, Wang R, Xie Y, et al
    Prognostic and Immunological Implications of Telomere Maintenance-Related Genes in Breast Cancer: A Mechanistic Exploration.
    Breast Cancer (Dove Med Press). 2025;17:1063-1082.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

24. CHAURASIA AK, Toohey PW, Bennett MT, Harris HC, et al
    Automated quantification of Ki-67 expression in breast cancer from H&E-stained slides using a transformer-based regression model.
    Breast Cancer Res. 2025;27:206.
    PubMed         Abstract available
    
    
25. QIU Y, Zhang R, Liu S, Wu L, et al
    Dynamic tumor-infiltrating lymphocytes predicts survival in HR+/HER2- early breast cancer: a pre-to-post neoadjuvant chemotherapy study.
    Breast Cancer Res. 2025;27:205.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

26. HASSAN AM, Hajj JP, Lewis JP, Fisher CS, et al
    Socioeconomic and ethnic disparities in breast cancer-related lymphedema and quality-of-life after immediate lymphatic reconstruction.
    Breast Cancer Res Treat. 2025;215:1.
    PubMed         Abstract available
    
    
27. OLIVEIRA LJC, Mano MS, Barrios C, Dienstmann R, et al
    The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6.
    Breast Cancer Res Treat. 2025;215:5.
    PubMed         Abstract available
    
    
28. HAMMER PM, Enamandram S, Ikeda DM, Lam MM, et al
    Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2025;215:10.
    PubMed         Abstract available
    
    
29. DALTON JC, Nierenberg TC, Leonard A, Liang J, et al
    Risk prediction models for malignancy upgrade in high-risk breast lesions: a qualitative systematic review.
    Breast Cancer Res Treat. 2025;215:3.
    PubMed         Abstract available
    
    
30. POST KE, Dunderdale L, Datta S, Varella L, et al
    Improving adjuvant endocrine therapy initiation among patients with breast cancer: a nurse-led, culturally sensitive pilot study.
    Breast Cancer Res Treat. 2025;215:7.
    PubMed         Abstract available
    
    
31. LIN J, Lipkowitz S, Hu H, Nealeigh M, et al
    Chronic inflammatory diseases and survival among breast cancer patients in the U.S. military health system.
    Breast Cancer Res Treat. 2025;215:4.
    PubMed         Abstract available
    
    
32. COLLIN SM, Lam C, Sredni ST, Haji-Noor ZM, et al
    HER2 testing results, practices, and preferences among pathologists and oncologists in the US community setting: a mixed-methods study.
    Breast Cancer Res Treat. 2025;215:2.
    PubMed         Abstract available
    
    
33. FREEMAN JQ, Schechter K, Nguyen LC, Omoleye OJ, et al
    Racial and ethnic disparities and socioeconomic determinants of male breast cancer mortality in the United States.
    Breast Cancer Res Treat. 2025;215:9.
    PubMed         Abstract available
    
    
34. XU Q, Li X, Deng X, Li M, et al
    Impact of lymph node status on the prognosis of female breast cancer patients who underwent immediate reconstruction after total mastectomy: a multi-institutional retrospective cohort study.
    Breast Cancer Res Treat. 2025;215:8.
    PubMed         Abstract available
    
    
35. NYQVIST-STRENG J, Chamalidou C, Kovacs A, Parris TZ, et al
    Worse survival despite indolent features for triple-negative invasive lobular carcinoma: a Swedish nationwide registry-based study.
    Breast Cancer Res Treat. 2025;215:12.
    PubMed         Abstract available
    
    

    
    Breast J

36. GOOCH JC, McClelland QY, Paschalis K, Anand M, et al
    Patient-Reported Outcomes After Same-Day Mastectomy Among Older Breast Cancer Patients: Results From a Prospective Clinical Trial.
    Breast J. 2025;2025:9953747.
    PubMed         Abstract available
    
    

    
    Cancer

37. MULLINS MA, Wang T, Furgal A, Hamilton AS, et al
    Changes in patient-reported primary care engagement in and communication about survivorship care from initial breast cancer treatment to longer-term survivorship.
    Cancer. 2025;131:e70181.
    PubMed         Abstract available
    
    
38. LAWRENCE L
    Switching to camizestrant prolonged PFS for patients with ER-positive, HER2-negative advanced breast cancer.
    Cancer. 2025;131:e70111.
    PubMed        
    
    
39. MAHMOUD MA, Edmonds CE, Barufaldi B, Nguyen A, et al
    Racial differences in quantitative background parenchymal enhancement on breast magnetic resonance imaging.
    Cancer. 2025;131:e70174.
    PubMed         Abstract available
    
    
40. FITCH KC, Yang JC, Ryan ES, Monuszko KA, et al
    Preferences of BRCA mutation carriers for attributes of risk-reducing surgical options for breast and ovarian cancer.
    Cancer. 2025;131:e70148.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

41. SHARIFF-MARCO S, Von Behren J, Chirikova E, Inamdar PP, et al
    Assessing upstream structural and social drivers of health in breast cancer survivorship: the Pathways Study Neighborhood Resource.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Res

42. MOHAMMAD MIRZAEI N, Hur C, Terry MB, Dalerba P, et al
    Modeling Early-Onset Cancer Kinetics Reveals Changes in Underlying Risk and the Impact of Population Screening.
    Cancer Res. 2025;85:4558-4570.
    PubMed         Abstract available
    
    

    
    Cell

43. ZHAO Y, Li Y, He Y, Wu J, et al
    Stereo-seq V2: Spatial mapping of total RNA on FFPE sections with high resolution.
    Cell. 2025;188:6554-6571.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

44. ZHANG J
    Diagnostic Heterogeneity and Healthcare Access Disparities: Latent Systemic Bias in Global Estimates of Male Breast Cancer Burden.
    Clin Breast Cancer. 2025;26:1-2.
    PubMed        
    
    
45. DEDEEPYA SD, Goel V, Desai NN
    Comment on "Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer".
    Clin Breast Cancer. 2025;26:3-4.
    PubMed        
    
    
46. ASADI F, Emadi E, Chaman R, Porouhan P, et al
    Feet Cooling As a Preventive Strategy against Chemotherapy-Induced Peripheral Neuropathy in Advanced Breast Cancer Patients: A Randomized Clinical Trial.
    Clin Breast Cancer. 2025;26:5-12.
    PubMed         Abstract available
    
    
47. KANDEMIR EA, Adam R, Roeper J, Ansmann L, et al
    Adherence to Multidisciplinary Tumor Board (MTB) Recommendations in Patients With Breast Cancer: The Results From Two Cancer Centers in Germany.
    Clin Breast Cancer. 2025;26:13-21.
    PubMed         Abstract available
    
    
48. NATANIA S A
    Letter to the editor regarding the article "Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer".
    Clin Breast Cancer. 2025;26:22.
    PubMed        
    
    
49. ZHANG W, Tang Z
    Comment on "The USP8/CEP55/CHMP6 Axis Orchestrates Triple-Negative Breast Cancer Progression by Regulating Ferroptosis and Macrophage M2 Polarization".
    Clin Breast Cancer. 2025;26:23-26.
    PubMed        
    
    

    
    Clin Cancer Res

50. RUGO HS, Kaklamani V, McArthur H, Wander SA, et al
    Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Nov 14. doi: 10.1158/1078-0432.CCR-25-3040.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

51. WOOLPERT KM, Collin LJ, Cronin-Fenton DP
    Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;232:116112.
    PubMed        
    
    
52. BUONAIUTO R, Martorana F, Marino P, Mangiacotti F, et al
    Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.
    Eur J Cancer. 2025;232:116102.
    PubMed         Abstract available
    
    
53. PUJOL P, Roca L, Lortholary A, Lasset C, et al
    Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).
    Eur J Cancer. 2025;231:116101.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

54. LOAP P, Cheptea C, Kirova Y
    Feasibility of a third breast-conserving treatment in ipsilateral breast cancer recurrence: A retrospective population-based analysis.
    Eur J Surg Oncol. 2025;52:111184.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

55. FUKUMITSU N, Shiba S, Shibuya K, Kobayashi D, et al
    Comprehensive Analysis of Data From a Nationwide Japanese Cohort on Particle Therapy for Metastatic Liver Tumors.
    Int J Radiat Oncol Biol Phys. 2025;123:1316-1322.
    PubMed         Abstract available
    
    
56. ARIF A, Khan AJ
    Pre-operative Radiotherapy in Locally Advanced Breast Cancer: A Narrative Review.
    Int J Radiat Oncol Biol Phys. 2025 Nov 17:S0360-3016(25)06437.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

57. YADAV RK, Miller KD
    Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard?
    J Clin Oncol. 2025 Nov 21:JCO2502336. doi: 10.1200/JCO-25-02336.
    PubMed        
    
    

    
    J Natl Cancer Inst

58. WORTELBOER N, Kent S, Blommestein HM, van Ommen-Nijhof A, et al
    Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.
    J Natl Cancer Inst. 2025 Nov 21:djaf334. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

59. DA SILVA LFCM, Carneiro FP, Motoyama AB
    MicroRNA Expression in Breast Cancer Patients, an Integrative Review.
    J Surg Oncol. 2025 Nov 16. doi: 10.1002/jso.70132.
    PubMed         Abstract available
    
    
60. AUBREY JM, Liefeld HR, Armstrong C, Levine A, et al
    Prospective Review of Practice Patterns in Breast Cancer Surgery Facilitates Rapid Practice Change, Reduced Clinical Variation, and Cost Savings.
    J Surg Oncol. 2025 Nov 16. doi: 10.1002/jso.70130.
    PubMed         Abstract available
    
    

    
    Lancet

61. ALLEMANI C, Minicozzi P, Morawski B, Lima CA, et al
    Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39
    Lancet. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383.
    PubMed         Abstract available
    
    

    
    Mod Pathol

62. KRINGS G, Shamir ER, Shelley Hwang E, Chen YY, et al
    Genetic Analysis of Early Neoplasia in the Breast: Next-Generation Sequencing of Flat Epithelial Atypia and Associated Ductal and Lobular Lesions.
    Mod Pathol. 2025;38:100820.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

63. AGGARWAL D, Wee TL, Satpathy S, Russo S, et al
    Longitudinal tracking of MALAT1 level over a breast cancer patient's course of treatment and disease progression.
    Mol Ther Oncol. 2025;33:201070.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

64. PARRISH M, Traugh N, Seraj M, Kuperwasser C, et al
    Field cancerization, accelerated aging, and immunosuppression: the rapid rise of hormone-sensitive and early-onset breast cancer.
    NPJ Breast Cancer. 2025;11:128.
    PubMed         Abstract available
    
    
65. GUIRGUIS MS, Adrada BE, Yam C, Tripathy D, et al
    Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer.
    NPJ Breast Cancer. 2025;11:129.
    PubMed         Abstract available
    
    
66. HUPPERT LA, Gliwa AS, Tait M, Quintal L, et al
    Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer.
    NPJ Breast Cancer. 2025;11:130.
    PubMed         Abstract available
    
    

    
    Oncogene

67. ZHOU L, Liu M, Liu F, Wang Z, et al
    Circular RNA CLASP1 modulates the GLI1/SNAIL axis and enhances macrophage polarization in breast cancer.
    Oncogene. 2025 Nov 17. doi: 10.1038/s41388-025-03627.
    PubMed         Abstract available
    
    
68. REINHARDT J, Dankbar B, Geers F, Werbenko E, et al
    Pharmacological inhibition of myostatin effectively ameliorates osteolytic lesions in syngeneic and xenograft breast cancer mouse models.
    Oncogene. 2025 Nov 17. doi: 10.1038/s41388-025-03622.
    PubMed         Abstract available
    
    

    
    Oncol Rep

69. JUNG E, Kim YJ, Lee K, Jang S, et al
    C?terminal HSP90 inhibitor NCT?58 impairs the cancer stem?like phenotype and enhances chemotherapy efficacy in TNBC.
    Oncol Rep. 2026;55:13.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

70. FAHMI NA, Cheng S, Overstreet J, Song Q, et al
    IPScan: Detecting novel intronic PolyAdenylation events with RNA-seq data.
    PLoS Comput Biol. 2025;21:e1013668.
    PubMed         Abstract available
    
    

    
    PLoS One

71. NGUYEN TTT, Pham PTV, Nguyen VAT, Nguyen TTT, et al
    Taxonomic characterization and cytotoxic potential of Vietnamese Ganoderma ellipsoideum against human breast cancer MCF-7 cells.
    PLoS One. 2025;20:e0336024.
    PubMed         Abstract available
    
    
72. SEKYERE AO, Iddrisu M, Mumuni HI, Konlan KD, et al
    Supportive care needs and challenges experienced by women diagnosed with breast cancer in Kumasi, Ghana: A qualitative exploratory study.
    PLoS One. 2025;20:e0336860.
    PubMed         Abstract available
    
    
73. ZHANG S, Zhang R, Xia Y, Cao D, et al
    Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events.
    PLoS One. 2025;20:e0336767.
    PubMed         Abstract available
    
    
74. PFISTER K, Friedl TWP, Hartkopf A, Mergel F, et al
    Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy.
    PLoS One. 2025;20:e0322156.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

75. 
    Correction for Goyette et al., Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
    Proc Natl Acad Sci U S A. 2025;122:e2530590122.
    PubMed        
    
    
76. KLOSOWSKI ML, Cronise KE, Palmer EP, McAuliffe K, et al
    Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance.
    Proc Natl Acad Sci U S A. 2025;122:e2423894122.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

77. GICHOYA JW, Trivedi H
    Are AI Models Using Shortcuts to Detect Breast Cancer Risk?
    Radiol Artif Intell. 2025;7:e250798.
    PubMed        
    
    

    
    Radiol Imaging Cancer

78. SHERIEF S, Kelil T
    Persistent Disparities Across Age, Race, and Ethnicity Revealed in Recent Report on U.S. Breast Cancer Mortality Trends.
    Radiol Imaging Cancer. 2025;7:e259032.
    PubMed        
    
    
79. EDIL BH JR, Agarwal H, Panneerselvam M, McNally LR, et al
    Monitoring Triple-Negative Breast Cancer with a Trop2-targeted Peptide PET Probe.
    Radiol Imaging Cancer. 2025;7:e259035.
    PubMed        
    
    
80. MARTIN DG, Hoover K, Smyth L, Bissell MB, et al
    Does the Addition of MRI Help in Breast Cancer Detection in Women with Low Breast Tissue Density in Two Canadian Population-based High-Risk Breast Screening Programs?
    Radiol Imaging Cancer. 2025;7:e250073.
    PubMed         Abstract available
    
    

    
    Radiology

81. HOU R, Grimm LJ, Marks JR, King LM, et al
    Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in Situ.
    Radiology. 2025;317:e243739.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

82. THOMSEN MS, Offersen BV
    Response to comment on "Quality assessment of 2705 treatment plans in the randomised Danish breast cancer Group Skagen trial 1".
    Radiother Oncol. 2025 Nov 19:111286. doi: 10.1016/j.radonc.2025.111286.
    PubMed        
    
    
83. GAO C, Wang L, Ma K, Chen Y, et al
    Comment on "Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1".
    Radiother Oncol. 2025 Nov 14:111285. doi: 10.1016/j.radonc.2025.111285.
    PubMed        
    
    
84. BILSKI M, Kuncman L, Orzechowska M, Cisek P, et al
    Survival outcomes and toxicity profile after CT-guided HDR brachytherapy (interventional radiotherapy) for liver oligometastases in breast cancer patients: The BRALIBREST real world multicenter study.
    Radiother Oncol. 2025;214:111280.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.